ICON currently has almost 15,250 employees in 94 locations in 40 countries. ICON offers a broad range of specialised services to assist pharmaceutical, biotechnology, medical device and government and public health organisations to bring new treatments to market faster. Our services span the entire lifecycle of product development, across a broad range of therapeutic areas, and can be adapted to suit small local trials or large global programs. We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.ICON services video
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
Organic growth bolstered through a number of strategic acquisitions which have broadened our service portfolio and have added scale to existing services.
ICON has assembled a leadership team with extensive industry experience.
ICON's press releases.
Quarter 3 reported revenue of $701.7 million representing a year on year decrease of 1.2% and 13.1% increase on Quarter 2 2020.
Adjusted earnings per share attributable to the Group for the quarter of $1.72, compared to $1.74 in Quarter 3 2019. Year to date earnings per share* attributable to the group of $4.63, compared to $5.06 for the equivalent prior year period.
Strong balance sheet and liquidity position remains, exceptional cash generation delivers net cash position of $360 million. Days sales outstanding reduced to 45 days from 56 days at September 30, 2019.
Successful refinance of the existing private placement $350 million senior notes on a delayed drawdown basis.
Raising full year 2020 revenue guidance to a range of $2,750 - $2,810 million. Full Year 2020 earnings per share guidance in the range of $6.35 - $6.50.